How Urolithin A from Pomegranates and Nuts Boosts Heart Performance by 80%: A Breakthrough in Treating Heart Failure

Exploring Urolithin A’s Role in Combating Heart Failure

According to НВ — Техно: Researchers at King’s College London have identified a natural compound called urolithin A, produced in the body after consuming pomegranates, walnuts, and certain berries, which dramatically enhances heart function. Their findings show that urolithin A can improve cardiac performance by up to 80%, reducing heart tissue scarring and preventing heart enlargement. This discovery offers promising new treatment possibilities for patients with heart failure with preserved ejection fraction (HFpEF), a condition that currently has very limited therapeutic options.

Understanding Heart Failure with Preserved Ejection Fraction and Its Risk Factors

HFpEF accounts for roughly half of all heart failure cases. In the UK alone, around 500,000 people live with this condition, characterized by a heart that can pump blood but has a stiffened muscle that struggles to relax. Key risk factors include:

• aging;
• high blood pressure;
• diabetes.

Treatment options are generally confined to managing these underlying conditions and making lifestyle adjustments.

Urolithin A activates the protein PKG1α, which plays a vital role in vascular function and cardiac muscle relaxation. The researchers also tested urolithin A on lab-grown human heart tissue derived from stem cells, noting significant improvement in muscle relaxation. Importantly, urolithin A has already undergone clinical trials involving humans, demonstrating a favorable safety profile.

Dr. Joseph Burgoyne emphasized, 'This form of heart failure is becoming increasingly prevalent due to aging populations and rising rates of obesity and diabetes. Despite its growing impact, treatment remains limited because the disease is complex and varies significantly among patients.'

This highlights the urgent need for further research into urolithin A’s therapeutic potential in heart failure treatment.

The discovery of urolithin A’s benefits could transform management of heart failure, a serious global health challenge especially as populations age. Given the scarcity of effective treatments, natural compounds like urolithin A offer new hope for patients suffering from this condition. Continued investigation is essential to validate its efficacy and safety, potentially opening new avenues in cardiovascular medicine.

As researchers continue to explore innovative treatments for heart conditions, recent findings from Australia shed light on the potential for human heart cell regeneration following a heart attack. This groundbreaking research underscores the complexities of cardiac recovery and may complement the benefits of new therapies targeting heart function, such as urolithin A, highlighting the evolving landscape of heart failure treatment options.